Chloroquine and Chloroquinoline Derivatives as Models for the Design of Modulators of Amyloid Peptide Precursor Metabolism

ACS Chemical Neuroscience

Volumn 6, Issue 4, 2015, Pages 559-569

  Melnyk, Patricia ^a,b,c   Vingtdeux, Valérie ^a,d   Burlet, Stéphane ^e   Eddarkaoui, Sabiha ^a,d   Grosjean, Marie Eve ^a,d   Larchanché, Paul Emmanuel ^a,b   Hochart, Guillaume ^a,b,c   Sergheraert, Christian ^a   Estrella, Cecilia ^e   Barrier, Mathieu ^e   Poix, Virginie ^e   Plancq, Pauline ^e   Lannoo, Cécile ^e   Hamdane, Malika ^a,d   Delacourte, André ^a,d   Verwaerde, Philippe ^e   Buée, Luc ^a,d   Sergeant, Nicolas ^a,d  

^a UNIV LILLE   (France)

^b Université de Lille 1 Sciences et Technologies   (France)

^c INSTITUT DE BIOLOGIE DE LILLE   (France)

^d JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^e AlzProtect   (France)

Author keywords

Alzheimer's disease; Amyloid precursor protein; Chloroquine; Piperazine

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BENZIMIDAZOLE; CHLOROQUINE; CHLOROQUINOLINE DERIVATIVE; PIPERAZINE; QUINOLINE; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA-PROTEIN (1-38); AMYLOID BETA-PROTEIN (1-42); APP PROTEIN, HUMAN; NEUROPROTECTIVE AGENT; PEPTIDE FRAGMENT; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CHEMICAL STRUCTURE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN SECRETION; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CELL DEATH; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; FRONTAL LOBE; HIPPOCAMPUS; LIVER MICROSOME; METABOLISM; PROTEIN STABILITY; TUMOR CELL LINE; WESTERN BLOTTING;

AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BLOTTING, WESTERN; CELL DEATH; CELL LINE, TUMOR; CHLOROQUINE; DRUG DESIGN; FEMALE; FRONTAL LOBE; HIPPOCAMPUS; HUMANS; MICE, INBRED C57BL; MICROSOMES, LIVER; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; PROTEIN STABILITY; QUINOLINES; WATER;

EID: 84927944644     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn5003013     Document Type: Article

References (47)

1. Vodicka, P., Lim, J., Williams, D. T., Kegel, K. B., Chase, K., Park, H., Marchionini, D., Wilkinson, S., Mead, T., Birch, H., Yates, D., Lyons, K., Dominguez, C., Beconi, M., Yue, Z., Aronin, N., and DiFiglia, M. (2014) Assessment of chloroquine treatment for modulating autophagy flux in brain of WT and HD mice J. Huntington's Dis. 3, 159 - 174
2. Korth, C., May, B. C. H., Cohen, F. E., and Prusiner, S. B. (2001) Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease Proc. Natl. Acad. Sci. U. S. A. 98, 9836 - 9841
3. Doh-ura, K., Iwaki, T., and Caughey, B. (2000) Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation J. Virol. 74, 4894 - 4897
4. Kocisko, D. A., Baron, G. S., Rubenstein, R., Chen, J., and Kuizon, S. 2003, New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products J. Virol. 77, 10288 - 10294
5. Klingenstein, R., Melnyk, P., Leliveld, R. S., Ryckebusch, A., and Korth, C. (2006) Similar Structure Activity Relationships of Quinoline Derivatives for antiprion and antimalarial effects J. Med. Chem. 49, 5300 - 5308
6. Ashfaq, U. A., Javed, T., Rehman, S., Nawaz, Z., and Riazuddin, S. (2011) Lysosomotropic agents as HCV entry inhibitors Virol. J. 8, 163 - 168
7. Blanchard, E., Belouzard, S., Goueslain, L., Wakita, T., Dubuisson, J., Wychowski, C., and Rouillé, Y. (2006) Hepatitis C virus entry depends on clathrin-mediated endocytosis J. Virol. 80, 6964 - 6972
8. Vasquez-Martin, A., Lopez-Bonetc, E., Cuti, S., Oliveras-Ferraros, C., Del Barco, S., Martin-Castillo, B., and Menendez, J. A. (2011) Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions Drug Resist. Updates 14, 212 - 223
9. Mahoney, E., Maddocks, K., Flynn, J., Jones, J., Cole, S. L., Zhang, X., Byrd, J. C., and Johnson, A. J. (2013) Identification of endoplasmic reticulum stress-inducing agents by antagonizing autophagy: a new potential strategy for identification of anti-cancer therapeutics in b-cell malignancies Leuk. Lymphoma 54, 2685 - 2692
10. Costedoat-Chalumeau, N., Leroux, G., Piette, J.-P., and Amoura, Z. (2010) Why all systemic lupus erythematosus patients should be given hydroxychloroquine treatment? Joint, Bone, Spine 77, 4 - 5
11. Suarez-Almazor, M. E., Belseck, E., Shea, B., Homik, J., Wells, G., and Tugwell, P. (2010) Antimalarials for treating rheumatoid arthritis Cochrane Database Syst. Rev. 4, CD000959
12. Ryckebusch, A., Deprez-Poulain, R., Maes, L., Debreu-Fontaine, M.-A., Mouray, E., Grellier, P., and Sergheraert, C. (2003) Synthesis and in Vitro and in Vivo Antimalarial Activity of N1-(7-Chloro-4-quinolyl)-1,4-bis(3-aminopropyl)piperazine Derivatives J. Med. Chem. 46, 542 - 557
13. Ryckebusch, A., Deprez-Poulain, R., Debreu-Fontaine, M.-A., Vandaele, R., Mouray, E., Grellier, P., and Sergheraert, C. (2003) Synthesis and Antimalarial Evaluation of New 1,4-Bis(3-aminopropyl)piperazine Derivatives Bioorg. Med. Chem. Lett. 13, 3783 - 3787
14. Bonnet, B., Soullez, D., Girault, S., Maes, L., Landry, V., Davioud-Charvet, E., and Sergheraert, C. (2000) Trypanothione Reductase Inhibition/Trypanocidal Activity Relationships in a 1,4-Bis(3-aminopropyl)piperazine Series Bioorg. Med. Chem. 8, 95 - 103
15. Yin, R. H., Tan, L., Jiang, T., and Yu, J. T. (2014) Prion-like Mechanisms in Alzheimer's Disease Curr. Alzheimer Res. 11, 755 - 64
16. Vingtdeux, V., Sergeant, N., and Buee, L. (2012) Potential contribution of exosomes to the prion-like propagation of lesions in Alzheimer's disease Front. Physiol. 3, 229 - 250
17. Vingtdeux, V., Hamdane, M., Loyens, A., Gelé, P., Drobecq, H., Bégard, S., Galas, M.-C., Delacourte, A., Beauvillain, J.-C., Buée, L., and Sergeant, N. (2007) Alkalizing drugs induce accumulation of amyloid precursor protein by-products in luminal vesicles of multivesicular bodies J. Biol. Chem. 282, 18197 - 18205
18. Kummer, M. P. and Heneka, M. T. (2014) Truncated and modified amyloid-beta species Alzheimer's Res. Ther. 6, 28 - 36
19. Yuyama, K., Yamamoto, N., and Yanagisawa, K. (2006) Chloroquine-induced endocytic pathway abnormalities: Cellular model of GM1 ganglioside-induced Abeta fibrillogenesis in Alzheimer's disease FEBS Lett. 580, 6972 - 6976
20. Bendiske, J. and Bahr, B. A. (2003) Lysosomal activation is a compensatory response against protein accumulation and associated synaptopathogenesis - an approach for slowing Alzheimer disease? J. Neuropathol. Exp. Neurol. 62, 451 - 463
21. De Strooper, B. (2010) Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process Physiol. Rev. 90, 465 - 494
22. Vingtdeux, V. and Marambaud, P. (2012) Identification and biology of α-secretase J. Neurochem. 120 (Suppl 1) 34 - 45
23. Pardossi-Piquard, R. and Checler, F. (2012) The physiology of the β-amyloid precursor protein intracellular domain AICD J. Neurochem. 120 (Suppl 1) 109 - 124
24. Takami, M., Nagashima, Y., Sano, Y., Ishihara, S., Morishima-Kawashima, M., Funamoto, S., and Ihara, Y. (2009) Gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment J. Neurosci. 29, 13042 - 13052
25. Karran, E., Mercken, M., and de Strooper, B. D. (2011) The amyloid cascade hypothesis for Alzheimer's Disease: an appraisal for the development of therapeutics Nat. Rev. Drug Discovery 10, 698 - 712
26. Matsumura, N., Takami, M., Okochi, M., Wada-Kakuda, S., Fujiwara, H., Tagami, S., Funamoto, S., Ihara, Y., and Morishima-Kawashima, M. (2014) Gamma-Secretase Associated with Lipid Rafts: Multiple Interactive Pathways in The Stepwise Processing of Beta-Carboxyl-terminal Fragment J. Biol. Chem. 289, 5109 - 5121
27. Yan, R. and Vassar, R. (2014) Targeting the beta secretase BACE1 for Alzheimer's disease therapy Lancet Neurol. 13, 319 - 329
28. Hall, A. and Patel, T. R. (2014) Gamma-Secretase modulators: Current status and future directions Prog. Med. Chem. 53, 101 - 45
29. Strömberg, K., Eketjäll, S., Georgievska, B., Tunblad, K., Eliason, K., Olsson, F., Radesäter, A. C., Klintenberg, R., Arvidsson, P. I., von Berg, S., Fälting, J., Cowburn, R. F., and Dabrowski, M. (2015) Combining an amyloid-beta (Aβ) cleaving enzyme inhibitor with a γ-secretase modulator results in an additive reduction of Aβ production FEBS J. 282, 65 - 73
30. Vingtdeux, V., Hamdane, M., Bégard, S., Loyens, A., Delacourte, A., Beauvillain, J.-C., Buée, L., Marambaud, P., and Sergeant, N. (2007) Intracellular pH regulates amyloid precursor protein intracellular domain accumulation Neurobiol. Dis. 25, 686 - 696
31. Tam, J. H., Seah, C., and Pasternak, S. H. (2014) The Amyloid Precursor Protein is rapidly transported from the Golgi apparatus to the lysosome and where it is processed into beta-amyloid Mol. Brain 7, 54 - 71
32. Melnyk, P., Sergeant, N., Buée, L., and Delacourte, A. (2006) Use of 1,4-bis(3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases. WO 2006/051489.
33. Vingtdeux, V., Hamdane, M., Gompel, M., Bégard, S., Drobecq, H., Ghestem, A., Grosjean, M.-E., Kostanjevecki, V., Grognet, P., Vanmechelen, E., Buée, L., Delacourte, A., and Sergeant, N. (2005) Phosphorylation of amyloid precursor carboxy-terminal fragments enhances their processing by a gamma-secretase-dependent mechanism Neurobiol. Dis. 20, 625 - 637
34. Lysosome accumulation ratios (LAR) was calculated in silico using the following equation: LAR = 1 + Σ n = 1 4 Σ i = 1 n 10 p K a i-pH L 1 + Σ n = 1 4 Σ i = 1 n 10 p K a i-pH 0 where pHL is the pH inside the lysosome (assumed to be pH 5.0) and pH0 in the cytosol (assumed to be pH 7.4). This equation is a derivation of the Henderson-Hasselbach equation, based on predicted values of drug p K a according to previous work of Hawley et al.(35) Values of p K a were calculated using ACD/p K a DB software from Advanced Chemistry Development Inc., Toronto, Canada.
35. Hawley, S. R., Bray, P. G., O'Neill, P. M., Park, B. K., and Ward, S. A. (1996) The role of drug accumulation in 4-aminoquinoline antimalarial potency. The influence of structural substitution and physicochemical properties Biochem. Pharmacol. 52, 723 - 733
36. Chasseigneaux, S. and Allinquant, B. (2012) Functions of Aβ, sAPPα and sAPPβ: Similarities and differences J. Neurochem. 120, 99 - 108
37. Ryckebusch, A., Deprez-Poulain, R., Debreu-Fontaine, M.-A., Vandaele, R., Mouray, E., Grellier, P., and Sergheraert, C. (2002) Parallel Synthesis and Antimalarial Activity of a Sulfonamide Library Bioorg. Med. Chem. Lett. 12, 2595 - 2598
38. Belyaev, N. D., Kellett, K. A., Beckett, C., Makova, N. Z., Revett, T. J., Nalivaeva, N. N., Hooper, N. M., and Turner, A. J. (2010) The Transcriptionally Active Amyloid Precursor Protein (APP) Intracellular Domain Is Preferentially Produced from the 695 Isoform of APP in a beta-Secretase-dependent Pathway J. Biol. Chem. 285, 41443 - 41454
39. Asai, M., Yagishita, S., Iwata, N., Saido, T. C., Ishiura, S., and Maruyama, K. (2011) An alternative metabolic pathway of amyloid precursor protein C-terminal fragments via cathepsin B in a human neuroglioma model FASEB J. 25, 3720 - 3730
40. Vorobyeva, A. G., Lee, R., Miller, S., Longen, C., Sharoni, M., Kandelwal, P. J., Kim, F. J., Marenda, D. R., and Saunders, A. J. (2014) Cyclopamine Modulates γ-Secretase-mediated Cleavage of Amyloid Precursor Protein by Altering Its Subcellular Trafficking and Lysosomal Degradation J. Biol. Chem. 289, 33258 - 33274
41. Goodger, Z. V., Rajendran, L., and Trutzel, A. (2009) Nuclear signaling by the APP intracellular domain occurs predominantly through the amyloidogenic processing pathway J. Cell Sci. 122, 3703 - 14
42. Ghosal, K., Vogt, D. L., Liang, M., Shen, Y., Lamb, B. T., and Pimplikar, S. W. (2009) Alzheimer's disease-like pathological features in transgenic mice expressing the APP intracellular domain Proc. Natl. Acad. U. S. A. 106 (43) 18367 - 18372
43. Ghosal, K. and Pimplikar, S. W. (2011) Aging and exitotxic stress exacerbate neural circuit reorganization in amyloid precursor protein intracellular domain transgenic mice Neurobiol. Aging 32 (12) 2320.e1 - 2320.e9
44. Ohkawara, T., Nagase, H., Koh, C.-S., and Nakayama, K. (2011) The amyloid precursor protein intracellular domain alters gene expression and induces neuron-specific apoptosis Gene 475, 1 - 9
45. Sergeant, N., David, J. P., Champain, D., Ghestem, A., Wattez, A., and Delacourte, A. (2002) Progressive decrease of amyloid precursor protein carboxy terminal fragments (APP-CTFs), associated with tau pathology stages, in Alzheimer's disease J. Neurochem. 81 (4) 663 - 672
46. Lipinski, C. A., Lombardo, F., Dominy, B. W., and Feeney, P. J. (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 46, 3 - 26
47. Sangster, J. (1997). Octanol-Water Partition Coefficients: Fundamentals and Physical Chemistry. Wiley Series in Solution Chemistry, Vol. 2, John Wiley and Sons, Chichester.